Join us for a webinar on how advances in target-based drug discovery are reshaping therapeutic design. We’ll explore ...

Insilico Medicine (“Insilico”), a world-leading artificial intelligence (AI)-driven drug discovery company, today announced a ...

Headlamp Health has launched Lumos AI®, a new decision-support platform designed to bring greater precision to neuroscience ...

Explore how Insilico collaborates with Servier to advance AI-driven drug discovery in oncology for unmet medical needs.

InSilico Medicine Cayman TopCo, an artificial intelligence drug discovery startup, said on Monday that it has secured a ...

Discover how AI is revolutionizing RNA drug development in a new article published in Engineering. Learn about the potential ...

Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody ...

Smart multi-target drugs are reshaping modern therapeutics by addressing the complex, interconnected pathways that drive diseases like Alzheimer’s, cancer, and major depressive disorder. Advances in ...

Insilico Medicine achieved an R&D collaboration with Servier valued at up to US$888 million, focused on discovering and developing innovative ...

Harbour BioMed inks long-term strategic collaboration with Lannacheng to advance next-generation radionuclide drug conjugates: Shanghai, China Tuesday, December 30, 2025, 13:00 Hr ...